ClinicalTrials.gg
CompletedNCT03282981BAART-DFUUpdated May 8, 2025Results posted

Beta Adrenergic Antagonist for the Healing of Chronic DFU

A Phase 3 interventional study of Timolol and Non biologically active gel in Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers and Non Healing Wound, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by VA Office of Research and Development · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 85 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
179th of 322
48 · median 60
Started
2018
with 13 others
Phase 3
32 of 381
3 open now
Registered
183rd of 381
by date
Lead sponsor
7 of 381
VA Office of Research and Development

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 179th largest by enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2018, is one of 32 in phase 3, and was the 183rd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic ulcers are very challenging to manage and are the most common cause of leg amputation. Many advanced treatments are expensive and difficult to use in the clinic or at home. Those newer therapies have shown little success in healing diabetic foot wounds. The investigators' laboratory and animal work has suggested that a safe medication, currently used as an eye drop for treatment of glaucoma, can heal these ulcers. The investigators are proposing to test this drop (timolol) directly on the surface of the foot ulcer to see if can improve healing faster than the current standard of care. To do this, the investigators propose a "randomized controlled trial" with two groups of patients with diabetic foot ulcers: one will receive standard of care with timolol while the other will receive standard of care with a gel (hydrogel, as placebo medicine).

Read the detailed description

The trial is designed as a prospective, randomized, double-blinded controlled study of subjects presenting with diabetic foot ulcers. The purpose of this study is to evaluate the superiority of Timoptic-XE therapy in conjunction with standard of care (SOC) treatment (Group A: Timoptic-XE + SOC) versus SOC (Group B: SOC + plus a non-biologically active gel, i.e., hydrogel, as placebo medication) in the clinical effectiveness in promoting wound healing and closure.

03

Conditions studied

  • Chronic Diabetic Foot Ulcers
  • Diabetic Neuropathic Ulcers
  • Non Healing Wound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject of any race 18 years old or older
  • Lower extremity ulcer located anywhere on the foot (as defined as beginning below the malleoli of the ankle):

    • Of more than 30 days duration and less than 2 years duration
    • Surface area between 0.5cm2 and 20cm2 (as measured with the Silhouette imaging system at randomization). The ulcer with largest surface area meeting inclusion criteria will be selected as index ulcer
    • If two ulcers present with the same surface area, the ulcer of the longest duration will be selected as index ulcer
  • Documented Ankle Brachial Index (ABI) between 0.8 and 1.2 on the study limb or toe pressure over 65mmHg within 3 months of screening phase
  • Documented report to rule out of ulcer of > 6 months duration
  • Subject or legally authorized representative understands and is willing to give written
  • Subject or legally authorized representative is willing and able to comply with a trial (13 to 17 days) of protocol-specified standard care prior to randomization and to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • Ulcer of non-diabetic etiology, such as venous, arterial and burn wounds
  • Index ulcer is less than 3 cm in distance from any other ulcer on the same extremity
  • There are greater than 3 ulcers on the study foot
  • Index ulcer presents with any of the following: cellulitis, osteomyelitis, exposed bone, tendon or fascia, capsule , purulent exudate or gangrene
  • Index ulcer shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs/symptoms:

    • increased warmth
    • increased pain
    • erythema
    • malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count > 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample)
  • Index ulcer surface area has decreased or increased > 40% between Screening and at Randomization (Visit 1) as assessed by the Silhouette imaging system
  • Has acquired or is known to be infected with (HIV)
  • Has active on the study foot
  • Has uncontrolled diabetes mellitus as defined by glycosylated > 12%
  • Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal
  • Has severe protein malnutrition as defined by serum albumin \< 2.5 g/dL
  • Has serum (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the
  • Has fatigue, palpitations, dyspnea, and/or angina at rest
  • Has a history, within the previous 12 months from date of Screening Visit, of alcohol or drug abuse, particularly methadone or heroin
  • Has received previous treatment with the following during the 60 days prior to Screening:

    • agents
    • radiation
    • chemotherapy
    • growth factors (epidermal growth factor, tumor necrosis factor, transforming growth factor, derived growth factor, etc.)

      • at the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active (or engineered) cellular or acellular product(s) at the site of the study ulcer, drug or device
  • Has been hospitalized for treatment of a diabetic foot ulcer within the previous 30 days from Screening
  • Has history of heart block 2nd and 3rd degree
  • Female who is pregnant or refuses to use adequate methods and is of childbearing age during the trial
  • Prisoners, institutionalized individuals or vulnerable population
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Timolol

    Timoptic-XE plus standard of care (SOC)

    Drug: Timolol

  • Placebo comparator
    SOC plus non biologically active gel

    SOC plus non biologically active gel (hydrogel as placebo medication)

    Drug: Non biologically active gel

Interventions

  • Topical application of Timolol on non-healing diabetic foot ulcers

    Also known as: Timoptic-XE

  • DrugNon biologically active gel

    Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers

    Also known as: Hydrogel

06

What researchers measure

Primary outcomes

  1. Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period

    Complete wound closure will be assessed by Investigators and is defined as 100% epithelialization of the wound site ("skin re-epithelialization without drainage or dressing requirements by Week 12). The primary outcome was the proportion of patients with complete wound healing by the end of the treatment phase, evaluated using Fisher's exact test.

    Time frame: 12 weeks

  2. Safety Outcome Measurement of Timolol Serum

    Safety outcome measurement of timolol serum during the treatment phase. Serum Timolol levels were assessed in all participants receiving SOC + Timolol. Most levels were below the detectable limit (\<0.22 ng/mL), suggesting minimal systemic absorption. Three participants exhibited detectable levels, with one case of a protocol deviation involving excessive application resulting in a serum level of 1.00 ng/mL. No systemic effects were observed in these cases, supporting the safety profile of topical Timolol.

    Time frame: 12 weeks

Secondary outcomes

  1. The Time to Wound Closure Between the Two Groups

    Time frame: 31 weeks

07

Results

Posted Apr 25, 2025

Participant flow

Recruitment started on July 24, 2018 and continued until August 30, 2023 from clinics at the VA Northern California Health Care System.

Participant flow — Overall Study
MilestoneTimololSOC Plus Non Biologically Active Gel
Started2127
Completed2124
Not completed03

Outcome measures

PrimaryPercentage of Complete Wound Closure, as Assessed Over a 12 Week Period

Complete wound closure will be assessed by Investigators and is defined as 100% epithelialization of the wound site ("skin re-epithelialization without drainage or dressing requirements by Week 12). The primary outcome was the proportion of patients with complete wound healing by the end of the treatment phase, evaluated using Fisher's exact test.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period
ParticipantsTimololSOC Plus Non Biologically Active Gel
Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period87
PrimarySafety Outcome Measurement of Timolol Serum

Safety outcome measurement of timolol serum during the treatment phase. Serum Timolol levels were assessed in all participants receiving SOC + Timolol. Most levels were below the detectable limit (\<0.22 ng/mL), suggesting minimal systemic absorption. Three participants exhibited detectable levels, with one case of a protocol deviation involving excessive application resulting in a serum level of 1.00 ng/mL. No systemic effects were observed in these cases, supporting the safety profile of topical Timolol.

Time frame:
12 weeks
Reported as:
Mean · ng/ml
Safety Outcome Measurement of Timolol Serum
ng/mlTimololSOC Plus Non Biologically Active Gel
Safety Outcome Measurement of Timolol Serum0.596 ± 0.315—
SecondaryThe Time to Wound Closure Between the Two Groups
Time frame:
31 weeks
Reported as:
Mean · weeks
The Time to Wound Closure Between the Two Groups
weeksTimololSOC Plus Non Biologically Active Gel
The Time to Wound Closure Between the Two Groups5.8 ± 1.09.2 ± 1.0

Adverse events

Collected over 5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Timolol2/21 (9.5%)0/21 (0%)0/21 (0%)
SOC Plus Non Biologically Active Gel5/27 (18.5%)2/27 (7.4%)0/27 (0%)
Most frequent serious events
Most frequent serious events
EventTimololSOC Plus Non Biologically Active Gel
InfectionInfections and infestations0/211/27
LightheadednessMetabolism and nutrition disorders0/211/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)TimololSOC Plus Non Biologically Active GelTotal
Mean68 ± 867 ± 868 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)TimololSOC Plus Non Biologically Active GelTotal
Female101
Male202747
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TimololSOC Plus Non Biologically Active GelTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American459
White161935
More than one race000
Unknown or Not Reported033
Region of Enrollment
Region of Enrollment(Participants)TimololSOC Plus Non Biologically Active GelTotal
United States212748
08

Study locations

1 site
  • VA Northern California Health Care System, Mather, CA
    Sacramento, California 95655-4200, United States
09

References and documents

Publications

  • Kaur R, Tchanque-Fossuo C, West K, Hadian Y, Gallegos A, Yoon D, Ismailyan L, Schaefer S, Dahle SE, Isseroff RR. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study. Trials. 2020 Jun 8;21(1):496. doi: 10.1186/s13063-020-04413-z. PubMed 32513257 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2023, 64 months.

Results were first posted in Apr 2025, 1 year 4 months after primary completion.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2017
First posted
Sep 14, 2017
StartActual
Jul 24, 2018
Primary completionActual
Dec 1, 2023
CompletionActual
Apr 30, 2024
Results first posted
Apr 25, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03282981
Collaborators
VA Northern California Health Care System
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Jul 24, 2018
Primary completion
Dec 1, 2023
Completion
Apr 30, 2024
Results posted
Apr 25, 2025
Last update
May 8, 2025

Study contacts

Sara E. Dahle, DPM MPH
principal investigator · VA Northern California Health Care System, Mather, CA
Rivkah R. Isseroff, MD
principal investigator · VA Northern California Health Care System, Mather, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion